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Abstract 
Introduction: Suicidal ideation is an emergent problem in the Emergency Department (ED) that often compli-
cates patient disposition and discharge. It has been shown that ketamine possesses fast acting antidepressant and 
anti-suicidal effects. This study was conducted to examine the effects of a single intravenous bolus of ketamine on 
patients with suicidal ideations in ED. Methods: Forty-nine subjects with suicidal ideations with or without an 
unsuccessful suicide attempt, received 0.2 mg/kg of ketamine. Scale for suicidal ideation (SSI) and Montgomery-
Abserg depression-rating scale (MADRS) were evaluated before and 40, 80 and 120 minutes after drug interven-
tion. The results were compared using the paired t-test and patients were followed up 10 days after ED admission 
for remnant suicide ideation. Results: SSI (df: 3, 46; F=80.7; p<0.001) and MADRS (df: 3, 46; F=87.2; p<0.001) 
scores significantly dropped after ketamine injection; the SSI score before and after 20, 40, and 80 minutes of ket-
amine injection were 23.0±6.7, 16.2±5.2, 14.3±4.3, and 13.6±4.0 respectively. The MADRS scores were 38.2±9.3, 
25.6±7.1, 22.7±6.3, and 22.1±5.95 at the same time intervals. 25.5% of patients were hospitalized, 63.3% received 
medications and 12.2% discharged. 6.2% of patients had suicidal ideations ten days after ED disposition.  Conclu-
sion: It seems that Ketamine could not be a good choice for fast reduction of suicidal ideations in ED patients. 
Further studies are needed to determine the optimal dose of ketamine for different patients. 
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Introduction: 1 
uicidal ideation is an emergent condition that de-
mands immediate attention. It has been shown 
that the time between decision and attempt in pa-
tients with suicidal ideations is about ten minutes (1). 
Various therapeutic interventions to decrease suicide 
risk have been proposed in serious psychiatric disor-
ders for long-term suicide prevention (2, 3). While the 
recognition of risk factors is very important for pre-
venting suicide, they fail to clarify the timing of a sus-
pected suicidal behavior. It has been shown that sub-
jects with mood disorders are at greater risk of suicide 
in the first two years after discharge (4).  
On the other hand it is known that during admission in 
emergency department (ED), immediately after dis-
charge from ED, and after starting antidepressants are 
the time points which the subjects are very vulnerable 
to suicidal ideations (5-9). Therefore, it is crucial to 
quickly intervene and prevent suicidal behavior in such 
conditions. It has also been shown that 43% of suicides 
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occur in the first month after discharge (5). This often 
complicates the disposition discharge of patient in the 
ED. A patient with significant suicide ideation cannot be 
safely discharged or admitted to general wards, regard-
less of the underlying medical condition.  
Different interventions for decreasing the possibility of 
suicidal risks are effective in long term. For example, 
lithium, clozapine, and risperidone are used for such a 
condition in EDs (10-12). However, the acute pharma-
cological management of suicidal risk remains compar-
atively under investigation (13). Considering the 
crowdedness of the majority of EDs, it is often impossi-
ble to offer standard care to patients with suicidal idea-
tion. In such settings, use of pharmaceutical interven-
tions can play an important role with a rapid effect on 
diminishing suicidal ideation.  
Numerous studies have shown the effect of single dose 
of intravenous (IV) ketamine on reducing depressive 
symptoms in approximately 70% of major depressive 
disorder (MDD) patients  in 24 hours after infusion (14-
18). The effects of Ketamine on reducing suicidal idea-
tion in severely depressed patients have been support-
ed by preliminary studies (19). Furthermore, a recent 
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effective on reducing the suicide ideation in patients 
refer to the ED (20) and those who have terminal ill-
ness(21).  
Considering to other studies, Ketamine is a favorable 
choice for emergency physicians because of many rea-
sons; its rapid effect as an anti-suicidal ideation causes 
that the patient can be discharged from the ED with 
early outpatient follow up. This is especially applicable 
in situations when an on call psychiatrist is not availa-
ble. Therefore, this study was performed to reaffirm the 
ketamine effect on patients with suicidal ideation in the 
ED. 
Methods: 
Study design and setting 
This single-blind clinical trial was done in Emergency 
Department of Imam Hossein hospital from October to 
September 2012. Participation in the study was volun-
tary and the consent form was obtained from their 
companions. Patients’ files were completed by the 
emergency physician and the information was kept 
strictly confidential. This research was confirmed by 
ethical committee of Imam Hossein hospital. 
Participants 
The patients (age over 16 years) were included in the 
study based on subjective expression of suicidal idea-
tions or recent suicidal actions at the time of admission 
to the department. Subjects were excluded if a diagnosis 
of alcohol or substance and drug abuse was made in the 
past three month or if they had received any medication 
for two weeks before ED admission.  
Intervention 
A single dose of ketamine hydrochloride infusion (0.2 
mg/kg, over one minute) was administered to the se-
lected subjects. This is the lowest dose of ketamine 
which has been described as effective in diminishing 
suicide ideation in previous studies (20, 21). Patients’ 
suicidal ideations were assessed by using Montgomery-
Asberg Depression Rating Scale (MADRS) and Scale for 
Suicidal Ideation (SSI). MADRS and SSI scales were 
completed for all of the patients in different times as 
follow: before injection and 40, 80, 120 minutes after 
infusion. The patients’ treatment followed standard ED 
protocols regardless of the study results; the outcome 
was followed up ten days after admission by a tele-
phone contact. 
Statistical analysis 
Descriptive analyses were performed by statistical 
software SPSS version 21.0 and graphs drawn by Excel 
2013. The SSI≥4 was considered as significant suicidal 
ideations and SSI<4 without significant suicidal idea-
tions. SSIs were compared before and after ketamine 
injection by paired t-test and repeated measures analy-
sis of variance. The p<0.05 was considered statistically 
significant. 
Results: 
Forty-nine patients were included in this study. Fifty 
one percent of patients were female (n=25) and 49% 
were male (n=24). The mean age of patients was 
32±10.8 years. Thirty-eight percent of patients (n=19) 
had a history of mental illness (bipolar and major de-
pression), 30% (n=15) previous suicidal ideations, 12 
% (n=6) psychiatric hospitalization, and 34% (n=17) 
self-injury. 
Table 1 shows the mean and SD of patients’ vital signs 
before and after injection of ketamine. Significant de-
crease was observed in the values of PR (89.8±8.8 vs. 
87.8±7.5; p<0.001) and RR (18.5±5.0 vs. 17.4.0±2.0 re-
spectively, p=0.04) ten minutes after ketamine injec-
tion. No significant difference was seen in the levels of 
BP (14.9±2.01 vs. 12.6±1.9; p=0.32) and O2SAT before 
and after ketamine injection (96.4±1.1 vs. 95.1±1.5; 
p=0.35). 
Mean and standard deviation of SSI scores before injec-
tion and at 40, 80 and 120 min after ketamine injection 
were respectively, 23.0±6.7, 16.2±5.2, 14.3±4.3 and 
13.6±4.0. The repeated measures analysis showed that 
the SSI scores decreased over time significantly. 
The most significant reduction was seen in the first 40 
minutes after injection (p<0.001) but, the score main-
tained a decreasing trend until 120 minutes (df: 3, 46; 
F=80.7; p<0.001). Mean and standard deviation of 
MADRS rating scales as well indicated a significant re-
duction in SSI scores at the times after injection (df: 3, 
46; F=87.2; p<0.001). MADRS rating scales before injec-
tion of ketamine was 38.2±9.3 and at the time of 40, 80 
and 120 minutes after injection were respectively 
25.6±7.1, 22.7±6.3 and 22.1±5.95. Once again the high-
est rate of reduction was at 40 min after the injection 
(p<0.001). 
25.5% of patients (n=12) were hospitalized, 63.3% 
(n=31) received medication, and 12.2% (n=6) dis-
charged. Follow-up 10 days after admission in ED 
showed that 85.7% of patients (n=44) did not have any 
suicidal thoughts, 8.2% (n=4) had hospitalized and 
Table 1: Vital signs measures before and after ketamine infusion  
Vital signs 
Time of injection 
p 
Before After 10 minute 
Pulse rate 89.8±8.8 87.8±7.5 <0.001 
Respiratory rate 18.5±5.0 17.4±2.0 0.04 
Blood pressure (Systolic/Diastolic) 12.6/8.1 12.6/8.2 0.32 
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6.1% (n=3) still had suicidal thoughts. 
Discussion: 
Suicide is one of the leading causes of death among 
young people especially those who have psychiatric 
disorders. In the past decade, many efforts have been 
done to prevent suicide attempts that the most im-
portant one was evaluating the risk factors of suicide 
and ways to prevent this problem (22). Suicidal idea-
tion is a medical emergency that requires immediate 
attention and treatment. Unfortunately, therapeutics 
used now for the rapid decrease in suicidal thoughts is 
often followed up with unpleasant consequences (23). 
In this study, the effect of ketamine was evaluated on 49 
patients admitted in ED with suicidal ideations and ac-
tions. Although suicidal ideation did not remove after 
ketamine injection, evaluation at 40, 80 and 120 min 
after infusion showed a significant reduction in SSI and 
MADRS scores (Figure 1 and 2). Previous studies have 
assessed the effect of ketamine infusion in patients with 
treatment-resistant depressive disorder and demon-
strated rapid beneficial effects on suicidal ideation (18, 
19). The results like previous studies show that keta-
mine is effective in reducing suicidal ideations. Yet in 
our study, the SSI score 40 minutes after the injection of 
ketamine dropped from 23±6 to 16±5, which although 
is significant, still above the previously set limit of 4. 
This might be due to the lower dose of ketamine used in 
our study compared to prior ones (0.5mg/kg) (19). It 
means that injection of 0.2mg/kg to patients was unable 
to eliminate suicidal ideation.  
A significant reduction was observed in the amount of 
RR and PR but all of the indices remained in normal 
limits and no danger threatened patients after injection 
of ketamine. The follow up of patients after ten days 
showed that some of them had still suicidal ideations 
(6.1%). This may reflect a shorter time of action for 
ketamine at the low dose of ketamine infusion (0.2 
mg/kg) used in this study. Therefore, if such a dose 
were used, adjunct treatments or repeated dose maybe 
also needed.  
It is clear that the results of current studies should be 
interpreted with more caution due to the small size of 
the population. The findings of this study showed that 
ketamine, as a modulating of glutaminergic system, 
could not be a good candidate for the quick treatment of 
suicidal ideations in the ED.  
However, further studies should be done to confirm the 
findings of this and previous studies; so that the optimal 
dose of ketamine for different patients and its lasting 
impact could be determined. 
Limitations 
The main limitation of present study is the small sample 
size. Another limitation of this study is the lack of a con-
trol group. However, because ketamine does not have 
any effect on suicidal ideations, this limitation did not 
affect the findings. 
Conclusion: 
It seems that Ketamine could not be a good choice for 
fast decrease of suicidal ideations in ED patients. Fur-
ther studies are needed to determine the optimal dose 
of ketamine for different patients. 
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 Figure 1: Scale for Suicidal Ideation (SSI) scores before 
and after ketamine infusion.   
Figure 2: Montgomery-Abserg Depression Rating Scale 
(MARDS) scores before and after ketamine infusion.  
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